Diovan, Plendil Cardiovascular Benefit Claims Are Off-Label Promotions - FDA
Executive Summary
Conclusive statements made by Novartis about Diovan's expected benefit in congestive heart failure trials drew a warning from FDA about promotions of unapproved uses.